Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21036626 | 0.91 | PTGS1 (0.32) | PTGS2PTGS1TLR4TLR2 | |
| SCHEMBL21036620 | 0.88 | PTGS2 (0.34) | PTGS2PTGS1CHRNB2CHRNA4 | |
| SCHEMBL21036628 | 0.86 | PTGS2 (0.33) | PTGS2PTGS1 | |
| SCHEMBL21036611 | 0.84 | PTGS1 (0.34) | PTGS2PTGS1 | |
| SCHEMBL21036612 | 0.83 | PTGS1 (0.33) | PTGS2PTGS1 | |
| SCHEMBL21036694 | 0.83 | TLR4 (0.36) | CHRNB2CHRNA4TLR4TLR2 | |
| SCHEMBL21036706 | 0.82 | CA12 (0.41) | CHRNB2CHRNA4TLR4TLR2 | |
| SCHEMBL21036614 | 0.81 | PTGS1 (0.32) | PTGS2PTGS1 | |
| SCHEMBL21036618 | 0.80 | GSR (0.35) | PTGS2PTGS1 | |
| SCHEMBL21036691 | 0.78 | KDM1A (0.33) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021231582-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF NEGATIVE SYMPTOMS AND COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | EUMENTIS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021188864-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20200377444-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019104020-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377444-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | NLN, SLC1A2, AANAT | PTGS2 1836/4885PTGS1 1526/4885CHRNB2 121/4885 |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | NLN, SLC1A2, AANAT | PTGS2 1836/4885PTGS1 1526/4885CHRNB2 121/4885 |
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | ACE2, ACE, MME | PTGS2 747/4885PTGS1 350/4885CHRNB2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.